Literature DB >> 16435094

[EGFR-expression in pulmonary neuroendocrine cell hyperplasia].

C Kuhnen1, B U Winter.   

Abstract

15 cases of pulmonary neuroendocrine cell hyperplasia (carcinoid-tumorlets, diffuse idiopathic pulmonary neuroendocrine cell hyperplasia/DIPNECH) and 20 neuroendocrine pulmonary tumors (10 carcinoid tumors, 5 large cell neuroendocrine, and 5 small cell neuroendocrine lung carcinomas) were immunohistochemically analyzed for the expression of epidermal growth factor receptor (EGFR, = HER-1). All cases of neuroendocrine cell hyperplasia exhibited a maximum EGFR expression (score 3 in 100% of cells) showing predominantly membranous, partly cytoplasmic staining. 4 ot the 10 carcinoid tumors were strongly positive for EGFR, whereas the other 6 were EGFR-negative. A total of 90% of large cell neuroendocrine and small cell neuroendocrine carcinomas were negative for EGFR. Overexpression of EGFR in pulmonary neuroendocrine cell hyperplasia might be significant for the pathogenesis of these lesions. As DIPNECH is characterized by clinical signs and symptoms including mild cough and obstructive functional impairment, a specific antagonistic therapeutic trial could aim at blocking EGFR/HER-1 or its subsequent signal transduction pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16435094     DOI: 10.1007/s00292-006-0819-0

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  13 in total

1.  Conditional clara cell ablation reveals a self-renewing progenitor function of pulmonary neuroendocrine cells.

Authors:  S D Reynolds; K U Hong; A Giangreco; G W Mango; C Guron; Y Morimoto; B R Stripp
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-06       Impact factor: 5.464

2.  Expression of epidermal growth factor receptor in human gastric and colonic carcinomas.

Authors:  W Yasui; H Sumiyoshi; J Hata; T Kameda; A Ochiai; H Ito; E Tahara
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

3.  The ultrastructural heterogeneity of potentially preneoplastic lesions in the human bronchial mucosa.

Authors:  S Gonzalez; D B von Bassewitz; E Grundmann; J A Nakhosteen; K M Müller
Journal:  Pathol Res Pract       Date:  1986-08       Impact factor: 3.250

4.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

5.  Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer.

Authors:  Shinichi Tsutsui; Shinji Ohno; Shigeru Murakami; Yoichi Hachitanda; Shinya Oda
Journal:  Breast Cancer Res Treat       Date:  2002-01       Impact factor: 4.872

6.  Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704.

Authors:  J T Price; H M Wilson; N E Haites
Journal:  Eur J Cancer       Date:  1996-10       Impact factor: 9.162

Review 7.  Epidermal growth factor receptor family in lung cancer and premalignancy.

Authors:  Wilbur A Franklin; Robert Veve; Fred R Hirsch; Barbara A Helfrich; Paul A Bunn
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

8.  Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors.

Authors:  R R Miller; N L Müller
Journal:  Am J Surg Pathol       Date:  1995-06       Impact factor: 6.394

9.  Significance of epidermal growth factor receptor in advanced ovarian cancer.

Authors:  G Scambia; P Benedetti Panici; F Battaglia; G Ferrandina; G Baiocchi; S Greggi; R De Vincenzo; S Mancuso
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

10.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

View more
  3 in total

1.  Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia with a central and peripheral carcinoid and multiple tumorlets: a case report emphasizing the role of neuropeptide hormones and human gonadotropin-alpha.

Authors:  Hanako Oba; Kazunori Nishida; Shingo Takeuchi; Hirohiko Akiyama; Koji Muramatsu; Masafumi Kurosumi; Toru Kameya
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

2.  Carriage of the EGF rs4444903 A>G functional polymorphism associates with disease progression in chronic HBV infection.

Authors:  S Cmet; C Fabris; G Fattovich; E Falleti; D Bitetto; A Cussigh; E Fontanini; E Fornasiere; M Pirisi; P Toniutto
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

3.  Diffuse idiopathic neuroendocrine cell hyperplasia: an unusual cause of breathlessness and pulmonary nodules.

Authors:  V M Tippett; C G Wathen
Journal:  BMJ Case Rep       Date:  2010-12-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.